Table 3.

Patient characteristics

Past medical history	Hypothyroidism
Medication	Thyroxine 100 μg Fluoxetine 40 mg daily Vitamin-D supplements Metoclopramide 10 mg prn
Alcohol Intake	None
Gall stone disease	None
Hyperlipidaemia	None
Weight/height/body mass index	105 kg/180 cm/32.41
Tumour :	Stage 4 (pT3a, cN0, M1) Clear Cell renal cancer. rhabdoid morphology Heng/International Metastatic Renal-Cell Carcinoma Database Consortium score: Poor3—expected median survival 7.8 months <1 year from time to diagnosis to systemic therapy. Haemoglobin <lower limit normal (120 g/L). Platelets>upper limit of normal.
Cancer therapies	Right cytoreductive nephrectomy, May 2019. Ipilimumab and Nivolumab, July–November 2019. Nivolumab (single agent) November 2019–December 2020
Symptoms	Bowels open 3–6 times a day with type 5–7 stool Intermittent steatorrhoea Pain helped by having his bowels open Nocturnal defecation once a week Urgency of defecation Bright red rectal bleeding Borborygmi weight